JPWO2022212384A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022212384A5
JPWO2022212384A5 JP2023560638A JP2023560638A JPWO2022212384A5 JP WO2022212384 A5 JPWO2022212384 A5 JP WO2022212384A5 JP 2023560638 A JP2023560638 A JP 2023560638A JP 2023560638 A JP2023560638 A JP 2023560638A JP WO2022212384 A5 JPWO2022212384 A5 JP WO2022212384A5
Authority
JP
Japan
Prior art keywords
cells
car
compound
fold
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513054A5 (https=
JP2024513054A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022358 external-priority patent/WO2022212384A1/en
Publication of JP2024513054A publication Critical patent/JP2024513054A/ja
Publication of JP2024513054A5 publication Critical patent/JP2024513054A5/ja
Publication of JPWO2022212384A5 publication Critical patent/JPWO2022212384A5/ja
Pending legal-status Critical Current

Links

JP2023560638A 2021-03-29 2022-03-29 リンパ腫の治療のためのcar t細胞療法および免疫調節化合物の組合せ Pending JP2024513054A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163167599P 2021-03-29 2021-03-29
US63/167,599 2021-03-29
US202163277134P 2021-11-08 2021-11-08
US63/277,134 2021-11-08
PCT/US2022/022358 WO2022212384A1 (en) 2021-03-29 2022-03-29 Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma

Publications (3)

Publication Number Publication Date
JP2024513054A JP2024513054A (ja) 2024-03-21
JP2024513054A5 JP2024513054A5 (https=) 2025-04-04
JPWO2022212384A5 true JPWO2022212384A5 (https=) 2025-04-04

Family

ID=81648162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560638A Pending JP2024513054A (ja) 2021-03-29 2022-03-29 リンパ腫の治療のためのcar t細胞療法および免疫調節化合物の組合せ

Country Status (9)

Country Link
US (1) US20240197871A1 (https=)
EP (1) EP4313126A1 (https=)
JP (1) JP2024513054A (https=)
KR (1) KR20240004390A (https=)
AU (1) AU2022252220A1 (https=)
BR (1) BR112023020012A2 (https=)
IL (1) IL307257A (https=)
MX (1) MX2023011370A (https=)
WO (1) WO2022212384A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 a1―표적화된 t―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
US20240018268A1 (en) 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
US20200078404A1 (en) * 2017-05-01 2020-03-12 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN118344338A (zh) * 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
WO2020097403A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Similar Documents

Publication Publication Date Title
TWI904120B (zh) Cd19和cd22嵌合抗原受體及其用途
US20250262318A1 (en) Methods and pharmaceutical composition for the treatment of cancer
JP2025134767A (ja) 癌の治療のためのキメラ抗原受容体
CN108136025B (zh) 一种使用免疫调节治疗癌症的新颖方法
TWI750110B (zh) 使用人類化抗-bcma嵌合抗原受體治療癌症
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
EP3423482A1 (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
MD3303379T2 (ro) Agenți de legare TIGIT și utilizări ale acestora
TW201828959A (zh) 精胺酸酶抑制劑組合療法
JP2021512107A5 (https=)
CN107847598B (zh) 用于癌症治疗的检查点抑制剂和全细胞分枝杆菌
RS59489B1 (sr) Kombinacija anti-cd30xcd16a antitela sa antagonističkim anti-pd-1 antitelom za terapiju
JPWO2020113194A5 (https=)
Masarova et al. Update on immunotherapy in AML and MDS: monoclonal antibodies and checkpoint inhibitors paving the road for clinical practice
TW201726172A (zh) 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑
CN113454116A (zh) Rank拮抗剂及其用途
JP2023544201A (ja) がんを処置するための免疫療法
TW202131950A (zh) 依序抗cd19療法
CN113316449A (zh) 胍那苄作为免疫疗法的佐剂
JPWO2022212384A5 (https=)
JPWO2021163389A5 (https=)
CN118766935A (zh) 治疗、预防、抑制或减少细胞因子释放的噁噻嗪二氧化物
WO2020234833A1 (en) Method for treating, preventing, inhibiting or reducing cytokine release
JPWO2021222330A5 (https=)
JPWO2019152743A5 (https=)